| PFG |
Report |
Q2 Non-GAAP Operating EPS (ex. significant variances) |
BEAT |
pred ~$2.38 vs. cons $2.33 |
MEDIUM |
| PFG |
Report |
Specialty Benefits (Dental) Loss Ratio, Q2 |
BEAT |
pred ~59.5% vs. cons ~61.0% (lower/favorable loss ratio) |
MEDIUM |
| PFG |
Report |
Investment Management non-affiliated net cash flow, Q2 |
MISS |
pred ~-$5.0B vs. cons ~-$2.0B |
LOW |
| PFG |
Guide |
FY2026 Non-GAAP Operating EPS growth guidance |
LOWER |
guide ~9-12% (~$9.02-$9.26 EPS) vs. cons $9.37 (+13.3%) (FY2026) |
MEDIUM |
| PFG |
Guide |
FY2026 Non-GAAP ROE guidance |
UNCHANGED |
guide ~15-17% vs. cons ~16.0% (FY2026) |
MEDIUM |
| PFG |
Guide |
International Pension segment earnings run-rate |
BETTER |
guide ~$75M vs. cons ~$65M quarterly run-rate (Q3 2026) |
MEDIUM |
| PFG |
Guide |
PRT (pension risk transfer) second-half pipeline commentary |
BETTER |
guide ~$3.0-4.0B H2 sales pickup vs. cons ~$2.0B (H2 2026) |
LOW |
| PFG |
Return |
Day-1 residual (stock − beta × S&P 500) |
+0.7% |
— |
MEDIUM |
| PFG |
Return |
5-day cumulative residual |
-1.0% (FADE) |
An EPS/margin beat plus favorable Specialty Benefits loss ratio should drive an initial pop, but reaffirmed (not raised) FY26 guidance of 9-12% EPS growth sits below the Street's embedded 13.3% full-year build, implying analysts must trim out-quarter estimates even after a Q2 beat. Combine that with unresolved net-flow softness in Investment Management, a still-light first-half PRT pipeline, and a stock already trading above several fair-value estimates (~$101.50 vs ~$107-109) after a 37%+ 12-month run, and the setup favors post-print mean reversion/fade over the following days as the initial reaction is unwound. |
MEDIUM |